1997
DOI: 10.1001/archderm.133.5.609
|View full text |Cite
|
Sign up to set email alerts
|

Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
23
0

Year Published

1999
1999
2011
2011

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 27 publications
(24 citation statements)
references
References 0 publications
1
23
0
Order By: Relevance
“…IFN␥ may also have a favorable effect on patients with SSc (90)(91)(92)(93). The importance of Th1/Th2 cytokines in fibrosis is supported by the finding that MRL/lpr mice lacking the IFN␥ receptor gene exhibit a syndrome that resembles human SSc (94).…”
Section: T Cell Activation and Cytokine Production In Ssc Leading To mentioning
confidence: 98%
“…IFN␥ may also have a favorable effect on patients with SSc (90)(91)(92)(93). The importance of Th1/Th2 cytokines in fibrosis is supported by the finding that MRL/lpr mice lacking the IFN␥ receptor gene exhibit a syndrome that resembles human SSc (94).…”
Section: T Cell Activation and Cytokine Production In Ssc Leading To mentioning
confidence: 98%
“…The entire pathology is linked to the activity of CD8 T cells, because depletion of CD8 T cells resulted in maintenance of normal lymphoid architecture during the course of infection. 17 Excessive collagen deposition in MHV-68-infected IFN-␥R Ϫ / Ϫ mice would suggest a dysregulated cytokine response, because overexpression of cytokines IL-4, IL-1␤, and TGF-␤1, and reduced expression of interferon-␥ have been shown to promote fibrosis 18,19 in, for example, systemic sclerosis 20,21 and murine models of fibrosis. 22,23 In the present study we have identified hitherto unreported pathologies in the mediastinal lymph nodes, lungs, and liver and have further characterized the changes in the spleen of MHV-68-infected IFN-␥R changes observed in these mice.…”
mentioning
confidence: 99%
“…Although preliminary data [19] suggested some, however, nonsignificant benefit of IFN-c treatment in patients with pulmonary fibrosis, other studies failed to show any effects of IFN-c in patients with systemic sclerosis [20][21][22]. Overall, there was only a moderate (nonsignificant) effect on skin sclerosis and no significant change in pulmonary function [23].…”
Section: Discussionmentioning
confidence: 99%
“…Overall, there was only a moderate (nonsignificant) effect on skin sclerosis and no significant change in pulmonary function [23]. However, these studies were limited by the fact that histopathological analysis of pulmonary fibrosis was lacking [19][20][21][22] and the dosage of IFN-c treatment was lower. All studies reported side-effects of IFN-c treatment in up to 65% of the study population and the mean drop-out rate resulting from sideeffects was 28% [23].…”
Section: Discussionmentioning
confidence: 99%